News Archive

MaxCyte®, Inc., a developer and supplier of cell engineering products and technologies to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announces data to be presented at the Keystone Symposia on Precision Genome Engineering summarizing in vitro and long-term preclinical toxicity and engraftment studies following targeted gene correction aimed at reversing mutations to wild-type sequence at clinically relevant levels in CD34+ hematopoietic stem cells (HSC) obtained from individuals with X-CGD. The oral and poster presentations will highlight use of MaxCyte’s proprietary, cGMP-compliant delivery platform in development of ex vivo gene-corrected cell therapies as a potential treatment for monogenic diseases. The Symposia is taking place January 8 to 12, 2017 in Breckenridge, Colorado.

Imagine that you found a drug at a government lab that others passed over which promises to cure, not just treat, certain blood cancers. You entered into a cooperative R&D agreement where your funding doubled the lab’s budget in a critical research area while they leverage the expertise of your company. You’re a small American company taking on the big boys, with a state of the art facility hoping to be first to market with a revolutionary therapy.

Blood cancer treatments may one day include special dietary restrictions: researchers have found that an essential amino acid plays a crucial role in the creation of blood stem cells—a discovery the scientists say could lead to a potential alternative to chemotherapy and radiation.

Formed in 1997, the Greater Rockville Partnership, now Rockville Economic Development, Inc. has evolved and grown to be an organization that has helped thousands of businesses and entrepreneurs in the City of Rockville. And we are so excited to hit 20 years of support and growth that we are going celebrate ALL YEAR LONG!

We have events and promotions planned throughout the year including our Business Appreciation Week, the REDI Commercial Broker Breakfast , the REDI Resource Meet up (R2M), as well as special 20th Anniversary events —you won’t want to miss any of them.

We are also offering 20th Anniversary sponsorship opportunities for companies looking for exposure by supporting our events throughout the year. If interested, you can contact Michael Steifvater via email or 301.315.8096.

Boston Scientific has made a name for itself with devices that are implanted into the body to prevent heart attacks. But through its Connected Patient Challenge, launched last month, the company is looking to get more involved in the kind of preventative medicine that’s based on the data generated by doctors, patients and the growth of wearable devices.

The healthcare industry’s transition toward value-based care is forcing providers to adopt new and emerging business models in lieu of traditional fee-for-service payment. At their core, these business models have the principle of value-based reimbursement, in which providers must meet certain quality care standards while controlling costs in order to get paid.

MdBio Foundation is hiring a team of enthusiastic individuals to operate the Verizon Innovative Learning explorer lab, a custom designed 45-foot bus that will travel to middle schools in the Washington, DC metropolitan area.  In addition to providing instruction to middle school students aboard the bus, the team will also assist in the development of associated curriculum, coordinating school visits, and moving and placement of the vehicle.

The explorer lab is currently being built in Burbank, California and will travel across the United States for a “road show.”  The road show will include a series of school visits and PR events between March and August 2017. In August 2017, the explorer lab will arrive in Washington, DC and will serve the DC Public School system for the 2017/2018 school year.

Cascadia Capital’s healthcare team contemplates the outlook for 2017, we believe the future of the industry will be affected by the agenda of the new administration. Where we believe this will have significant impact is on expense containment and prioritization of the wellness agenda.

The NHLBI’s Strategic Vision rests on four mission-driven goals that will benefit from sustained Institute focus. Eight objectives organize the 132 Research Priorities.

Headquartered in Hayward, California, Intarcia Therapeutics is a force to be reckoned with in the biotech world. It has raised over $1 billion in total equity funding and recently acquired Phoundry Pharmaceuticals for an undisclosed amount.

It hasn’t gone public.